利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.013 秒)

    Drug carrier and drug carrier kit for inhibiting fibrosis
    4.
    发明公开
    Drug carrier and drug carrier kit for inhibiting fibrosis 审中-公开
    药物载体和Wirkstoffträgerkit抑制纤维化

    公开(公告)号：EP2730277A3

    公开(公告)日：2014-07-23

    申请号：EP13193438.2

    申请日：2005-12-22

    申请人： NITTO DENKO CORPORATION

    发明人： Niitsu, Yoshiro ,  Kato, Junji ,  Sato, Yasushi

    IPC分类号： A61K9/107 ,  A61K9/127 ,  A61K31/7088 ,  A61K31/07 ,  A61K45/06 ,  A61K9/50 ,  A61K9/51 ,  A61P1/16 ,  A61P1/18 ,  A61P43/00 ,  A61K47/48

    摘要： A stellate cell-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, a stellate cell-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of stellate cells, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

    Drug carrier and drug carrier kit for inhibiting fibrosis
    6.
    发明公开
    Drug carrier and drug carrier kit for inhibiting fibrosis 审中-公开
    用于抑制纤维化的药物载体和药物载体试剂盒

    公开(公告)号：EP2730277A2

    公开(公告)日：2014-05-14

    申请号：EP13193438.2

    申请日：2005-12-22

    申请人： NITTO DENKO CORPORATION

    发明人： Niitsu, Yoshiro ,  Kato, Junji ,  Sato, Yasushi

    IPC分类号： A61K9/107 ,  A61K9/127 ,  A61K31/7088 ,  A61K31/07 ,  A61K45/06 ,  A61K9/50 ,  A61K9/51 ,  A61P1/16 ,  A61P1/18 ,  A61P43/00

    摘要： A stellate cell-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, a stellate cell-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of stellate cells, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

    摘要翻译： 含有类维生素A衍生物和/或维生素A类似物作为成分的星状细胞特异性药物载体; 使用它的药物递送方法; 含有它的药物; 以及使用该药物的治疗方法。 通过将药物载体与类视黄醇衍生物如维生素A或维生素A类似物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。 结果，可以有效地抑制或预防星状细胞相关疾病，同时使副作用最小化。 作为抑制星状细胞活性或生长的药物，例如，可以将针对作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。 因此，可以同时抑制I型向IV型胶原的分泌，进而可以有效抑制纤维化。